Mallinckroedt Pharmaceuticals is testing a new hepatitis C drug that’s expected to help people who have already had the virus, the company said Thursday.
The company said it will test the drug out in patients who are at high risk of contracting the disease.
Mallinkeydt said it is in discussions with health care providers and others about how to help with the drug’s effectiveness.
The drug, called H3, was first approved in the U.S. in October, and was later approved in Japan.
Mallineckrodts drug, H3v2, can lower the body’s temperature, reduce inflammation and slow the body from going into shock, the pharmaceutical company said in a news release.
It’s a small molecule drug with no side effects.
In the U, it’s also approved for use in people with type 1 diabetes.
It is not a cure.
The National Institutes of Health said it was studying Mallin-ckrod’s drug and other hepatitis C drugs.
Malli-ckdts company is also working on a hepatitis C treatment called viroclavir, which is also approved in Europe.
The U.K. government said in April it was reviewing whether to allow the drug to be used in people who are over age 50.
Mallieckrodtz drug is expected to cost $7,500 for a month of six pills.
A small-scale study published in the journal PLOS One in June suggested the drug could be effective in treating people who can’t afford to pay for treatment.
In April, a small-to-medium-scale trial also suggested it could help people with advanced stages of the virus.
Mallitcct’s drug is being tested in patients with chronic liver disease, those who have cirrhosis of the liver, and those who are HIV-positive.
Mallinkrods drug was developed by pharmaceutical company Eli Lilly & Co. The first pill, MalliCct, costs $13,900 and is available as a monthly treatment in the United States and Japan.
The second pill, which MalliTcct, is available to buy for $12,900 a month, is also available in the countries of Europe and Japan, Mallinct said in its news release Thursday.
Mallionckrods is also testing the drug in patients that are HIV positive.
“The company is actively pursuing new treatment approaches and will provide more details when available,” Mallinekdts statement said.
Mallinetics drug, MallisV2, is approved for the treatment of advanced hepatitis C in Europe, as well as Japan.
It costs $8,000 a month for a treatment of two weeks.
The Drug Enforcement Administration in July said it would give MalliV2 a higher priority, saying it is a potential new option for the United Nations AIDS Emergency Committee.
The DEA said the agency has received more than 1,500 reports of patients seeking the drug, and it has received at least one case of hepatitis C related to the drug.
The agency also said it has made several efforts to provide drug access to patients.